Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130976 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HPGDCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL18783165 | 0.80 | ALDH1A1 (0.39) | ALDH1A1HPGDGABRA1GABRB2 | |
| SCHEMBL21524054 | 0.78 | ALDH1A1 (0.38) | ALDH1A1HPGDGABRA1GABRB2 | |
| SCHEMBL10024837 | 0.78 | HPGD (0.48) | ALDH1A1HPGDGABRA1GABRB2 | |
| SCHEMBL14260574 | 0.77 | ALDH1A1 (0.37) | ALDH1A1HPGDGABRA1GABRB2 | |
| SCHEMBL13514040 | 0.77 | — | — | |
| SCHEMBL14380270 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HPGDCYP3A4GABRA1GABRB2 | |
| SCHEMBL10130736 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HPGDCYP3A4GABRA1GABRB2 | |
| SCHEMBL10130758 | 0.73 | ALDH1A1 (0.38) | ALDH1A1HPGD | |
| SCHEMBL13026624 | 0.71 | AHR (0.38) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| EP-1506214-B1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARM INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | ALDH1A1 452/4885HPGD 248/4885CYP2E1 44/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | ALDH1A1 452/4885HPGD 248/4885CYP2E1 44/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | ALDH1A1 353/4885HPGD 130/4885CYP2E1 56/4885 |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | HDAC6, SI, HDAC3 | ALDH1A1 2671/4885HPGD 1779/4885CYP2E1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.